Skip to main content

Table 4 Median (range) HGF levels in phase 2, nadroparin group, benign vs. malignant tumours

From: Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications

HGF phase_2

Cmax (ng/ml)

p

HGF_pre benign

0.58 (0.38-1.68)

0.584

HGF_pre malignant

0.40 (0.33-1.03)

HGF_post1 benign

3.70 (2.76-6.19)

0.155

HGF_post1 malignant

4.98 (3.15-6.25)

HGF_post2 benign

3.18 (1.91-5.73)

0.030

HGF_post2 malignant

5.35 (4.20-6.08)

HGF_post3 benign

2.96 (2.43-5.64)

0.867

HGF_post3 malignant

2.78 (2.08-4.08)

Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us